Date: 2014-10-28
Type of information: Series A financing round
Company: Imevax (Germany)
Investors: Wellington Partners (UK), BioMedPartners (Switzerland), EMBL Ventures (Germany), Santo Venture Capital (Germany)
Amount: €7.5 million
Funding type: series A financing round
Planned used: The funds will be used to advance lead candidate IMX 101 through clinical trials before partnering. IMX 101 is a highly specific vaccine against Helicobacter pylori (H. pylori). Chronic infections of the stomach with H. pylori are the most common bacterial infections worldwide and lead to gastritis, stomach ulcers and potentially stomach cancer. Due to the high global infection rate and the decreasing efficacy of existing antibiotics against H. pylori plus the poor safety profile of these treatments, there exists a high medical need and a significant commercial interest in a H. pylori vaccine.
Others: * On October 28, 2014, ImevaX, a specialist in vaccines against pathogens of chronic infectious diseases, announces the completion of a € 7.5 million Series A financing round. The round was led by Wellington Partners. Co-lead investors were BioMedPartners with their BioMedInvest-II LP fund, EMBL Ventures and Santo Venture Capital. ImevaX is a 2014 spin-out from the Technische Universität München (TUM) and has been recently awarded a € 5.9 million financing from the GO-Bio Phase II program of the Federal Ministry of Education and Research (BMBF). Dr Markus Hosang of BiomedPartners, Dr Jan Adams of EMBL Ventures and Dr Ulrich Granzer of Granzer Regulatory Consulting have also joined the Advisory Board of ImevaX.
Therapeutic area: Infectious diseases
